{"log_id": 1371469854425757134, "direction": 0, "words_result_num": 54, "words_result": [{"probability": {"variance": 3.4e-05, "average": 0.996447, "min": 0.975509}, "location": {"width": 775, "top": 152, "height": 45, "left": 221}, "words": "对哺乳的影响:大鼠乳汁中可检测出药物相关物质,但本品是否经人乳汁排出尚不清楚"}, {"probability": {"variance": 0.010506, "average": 0.976138, "min": 0.464349}, "location": {"width": 538, "top": 189, "height": 42, "left": 181}, "words": "由于许多药物可经人乳汁排出,因此哺乳妇女不宜服用本品"}, {"probability": {"variance": 1.7e-05, "average": 0.997227, "min": 0.988214}, "location": {"width": 111, "top": 233, "height": 25, "left": 191}, "words": "【儿童用药】"}, {"probability": {"variance": 1.7e-05, "average": 0.997618, "min": 0.983194}, "location": {"width": 788, "top": 247, "height": 46, "left": 221}, "words": "目前尚无18岁以下患者使用本品的有效性及安全性资料,故18岁以下患者不应服用本"}, {"probability": {"variance": 0, "average": 0.966151, "min": 0.966151}, "location": {"width": 23, "top": 301, "height": 25, "left": 182}, "words": "品"}, {"probability": {"variance": 1.8e-05, "average": 0.997032, "min": 0.987722}, "location": {"width": 107, "top": 330, "height": 25, "left": 193}, "words": "【老年用药】"}, {"probability": {"variance": 0.019404, "average": 0.9584, "min": 0.38606}, "location": {"width": 378, "top": 353, "height": 36, "left": 225}, "words": "老年患者服用本品毋需因年龄而调剂量"}, {"probability": {"variance": 0.000143, "average": 0.991406, "min": 0.963391}, "location": {"width": 153, "top": 390, "height": 28, "left": 190}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.000127, "average": 0.99452, "min": 0.951658}, "location": {"width": 418, "top": 413, "height": 37, "left": 225}, "words": "与其它药物的相互作用及其它形式的相互作用"}, {"probability": {"variance": 1.9e-05, "average": 0.997018, "min": 0.978942}, "location": {"width": 786, "top": 434, "height": 44, "left": 224}, "words": "经细胞色素P450代谢的药物:体外药物代谢试验表明,在临床使用剂量下,罗格列酮"}, {"probability": {"variance": 0.003065, "average": 0.988162, "min": 0.619787}, "location": {"width": 822, "top": 463, "height": 43, "left": 186}, "words": "不抑制主要的P450。体外试验资料证实,罗格列主要通过CYP2C8代谢,极少部分经CYP2C"}, {"probability": {"variance": 0, "average": 0.999815, "min": 0.999729}, "location": {"width": 43, "top": 508, "height": 24, "left": 186}, "words": "代谢"}, {"probability": {"variance": 0.00013, "average": 0.99472, "min": 0.935348}, "location": {"width": 781, "top": 516, "height": 45, "left": 226}, "words": "尼莫地平和口服避孕药(炔雌醇和炔诺酮)主要经CYP3A途径代谢,因此与本品("}, {"probability": {"variance": 0.008366, "average": 0.966186, "min": 0.577372}, "location": {"width": 733, "top": 546, "height": 43, "left": 185}, "words": "毫克,每日2次)合用,不会对上述一药物产生具有临床意义的药代动力学影响"}, {"probability": {"variance": 0.00532, "average": 0.982652, "min": 0.536509}, "location": {"width": 794, "top": 571, "height": 45, "left": 225}, "words": "格列本脲:对于服用格列本脲后病情稳定的糖尿病患者,本品(2毫克/次,每口2次)"}, {"probability": {"variance": 0.011082, "average": 0.968541, "min": 0.441824}, "location": {"width": 828, "top": 599, "height": 45, "left": 187}, "words": "与格列本脲(3.75毫克/日全10毫克/日)合用7天,不会改变其24小时的平均稳态血糖"}, {"probability": {"variance": 0, "average": 0.999943, "min": 0.999889}, "location": {"width": 45, "top": 647, "height": 24, "left": 184}, "words": "水平"}, {"probability": {"variance": 0.000776, "average": 0.984341, "min": 0.881695}, "location": {"width": 760, "top": 654, "height": 42, "left": 248}, "words": "甲双胍:对于健康受试者,本品(2毫克/次,每日2次)与甲双胍(500毫克/次,"}, {"probability": {"variance": 0.000996, "average": 0.988673, "min": 0.844697}, "location": {"width": 653, "top": 683, "height": 45, "left": 186}, "words": "每日2次)合用4天,不会改变本品及二甲双胍的稳态药代动参数"}, {"probability": {"variance": 0.009801, "average": 0.964811, "min": 0.458578}, "location": {"width": 788, "top": 705, "height": 52, "left": 227}, "words": "阿卡波糖:健康受试者服用阿卡波糖(100毫克/次,每3次天对单剂口服本品"}, {"probability": {"variance": 0.000147, "average": 0.992301, "min": 0.956231}, "location": {"width": 228, "top": 752, "height": 26, "left": 188}, "words": "的药代动力学参数无影响"}, {"probability": {"variance": 0.037005, "average": 0.863403, "min": 0.358873}, "location": {"width": 782, "top": 760, "height": 52, "left": 228}, "words": "地高辛:健康受试者连服本品《8毫克次,每日1天,高辛0375毫克"}, {"probability": {"variance": 0.022084, "average": 0.934766, "min": 0.407546}, "location": {"width": 418, "top": 799, "height": 36, "left": 188}, "words": "次,每1次)的稳念药代动力学参数无影"}, {"probability": {"variance": 0.019502, "average": 0.952063, "min": 0.362459}, "location": {"width": 478, "top": 823, "height": 37, "left": 230}, "words": "华法林:连续服用本对华法林对映体的稳态药代动"}, {"probability": {"variance": 0.033649, "average": 0.883973, "min": 0.474331}, "location": {"width": 178, "top": 815, "height": 30, "left": 737}, "words": "家参数无影响。"}, {"probability": {"variance": 0.012042, "average": 0.969384, "min": 0.487866}, "location": {"width": 784, "top": 845, "height": 42, "left": 231}, "words": "乙醇:服用本品的2型糖尿病患者单次饮用中等量的乙停不会增加其急性低血糖的发"}, {"probability": {"variance": 2e-06, "average": 0.998422, "min": 0.995874}, "location": {"width": 102, "top": 889, "height": 24, "left": 190}, "words": "生的危险性"}, {"probability": {"variance": 0.005953, "average": 0.976, "min": 0.590566}, "location": {"width": 567, "top": 903, "height": 39, "left": 229}, "words": "雷尼替丁:健康受试者服用雷尼替丁(150毫克/次,每口2次"}, {"probability": {"variance": 2.6e-05, "average": 0.997704, "min": 0.9851}, "location": {"width": 146, "top": 901, "height": 26, "left": 872}, "words": "不会改变罗格列"}, {"probability": {"variance": 0.002765, "average": 0.980382, "min": 0.727885}, "location": {"width": 816, "top": 927, "height": 42, "left": 191}, "words": "酮单剂口服或静脉给药的药代动力学参数,该结果表明胃肠道PH值升高不影响本品的吸收"}, {"probability": {"variance": 0.005126, "average": 0.971447, "min": 0.738198}, "location": {"width": 254, "top": 966, "height": 32, "left": 229}, "words": "配伍禁忌:无已知配伍禁忌"}, {"probability": {"variance": 2e-06, "average": 0.998936, "min": 0.997144}, "location": {"width": 107, "top": 1003, "height": 24, "left": 201}, "words": "【药物过量】"}, {"probability": {"variance": 0.000409, "average": 0.994075, "min": 0.878935}, "location": {"width": 786, "top": 1016, "height": 44, "left": 230}, "words": "目前尚缺乏人体药物过量的资料。健康受试者单剂口服本品最高达20毫克,仍可很好"}, {"probability": {"variance": 9.2e-05, "average": 0.99513, "min": 0.961806}, "location": {"width": 649, "top": 1050, "height": 43, "left": 187}, "words": "耐受。一旦发生药物过量,应根据病人的临床表现给予相应的支持治疗"}, {"probability": {"variance": 4.9e-05, "average": 0.995674, "min": 0.980317}, "location": {"width": 112, "top": 1096, "height": 26, "left": 197}, "words": "【药理毒理】"}, {"probability": {"variance": 1e-06, "average": 0.998419, "min": 0.997671}, "location": {"width": 85, "top": 1125, "height": 24, "left": 232}, "words": "药理作用"}, {"probability": {"variance": 0.002044, "average": 0.982924, "min": 0.771709}, "location": {"width": 793, "top": 1135, "height": 45, "left": 229}, "words": "2型糖尿病的主要病理生理学特征为胰岛素抵抗。本品属噻唑烷二酮类抗糖尿病药。通"}, {"probability": {"variance": 0.0053, "average": 0.980477, "min": 0.588307}, "location": {"width": 808, "top": 1165, "height": 44, "left": 190}, "words": "过提高靶组织对胰岛素的敏感性而有效地控制血糖。本品为过氧化物酶体增殖激活受体"}, {"probability": {"variance": 0.000135, "average": 0.994974, "min": 0.960454}, "location": {"width": 215, "top": 1194, "height": 27, "left": 806}, "words": ")的高选择性、强效激"}, {"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 49, "top": 1213, "height": 21, "left": 205}, "words": " (PPAR"}, {"probability": {"variance": 0.00139, "average": 0.987647, "min": 0.788662}, "location": {"width": 830, "top": 1220, "height": 45, "left": 192}, "words": "动剂。人体内胰岛素的主要靶组织如肝脏、脂坊和肌肉组织中,均存在PPAR受体,本品激活"}, {"probability": {"variance": 0, "average": 0.99991, "min": 0.99991}, "location": {"width": 56, "top": 1176, "height": 90, "left": 1136}, "words": ")"}, {"probability": {"variance": 0.004465, "average": 0.983704, "min": 0.571773}, "location": {"width": 828, "top": 1248, "height": 45, "left": 193}, "words": "PPAR-核受体,可对参与葡萄糖生成,转运和利用的胰岛素反应基因的转录进行调控。此"}, {"probability": {"variance": 0.008297, "average": 0.963881, "min": 0.663671}, "location": {"width": 272, "top": 1289, "height": 29, "left": 193}, "words": "外, PPARY反应基因(PPAR"}, {"probability": {"variance": 0.000308, "average": 0.990156, "min": 0.93312}, "location": {"width": 316, "top": 1277, "height": 30, "left": 703}, "words": "也参与脂肪酸代谢的调节。临床研"}, {"probability": {"variance": 0.005877, "average": 0.982496, "min": 0.498651}, "location": {"width": 828, "top": 1303, "height": 43, "left": 192}, "words": "究中空腹血糖(FPG)和HbAc检测结果表明,该药可改善血糖控制情况,同时伴有血胰岛"}, {"probability": {"variance": 0.007086, "average": 0.962448, "min": 0.604777}, "location": {"width": 815, "top": 1330, "height": 43, "left": 193}, "words": "素和C肽水平降低,也可使餐后血糖和影岛素水平下降。本品对血糖控制的改善作用较持久"}, {"probability": {"variance": 1e-06, "average": 0.998123, "min": 0.997112}, "location": {"width": 132, "top": 1374, "height": 26, "left": 196}, "words": "可维持达52周"}, {"probability": {"variance": 0.005186, "average": 0.977335, "min": 0.581157}, "location": {"width": 786, "top": 1382, "height": 45, "left": 235}, "words": "本品的抗糖尿病作用已在2型糖尿病的动物模型(由一靶组织的胰岛素抵抗而出现高血"}, {"probability": {"variance": 0.005421, "average": 0.970106, "min": 0.689295}, "location": {"width": 831, "top": 1410, "height": 45, "left": 193}, "words": "糖症和或糖耐量降低)中得到提示,可有效地降低ob/ob肥胖小鼠、db/db糖尿病小鼠和"}, {"probability": {"variance": 0.013833, "average": 0.951875, "min": 0.403197}, "location": {"width": 829, "top": 1437, "height": 48, "left": 194}, "words": " Lucker肥胖大鼠的血糖,减轻其高胰岛素症,并可延缓dib/db小鼠和 Zucker肥胖大鼠模"}, {"probability": {"variance": 5.5e-05, "average": 0.996386, "min": 0.956663}, "location": {"width": 828, "top": 1465, "height": 48, "left": 195}, "words": "型的糖尿病发展。动物研究提示,本品的抗糖尿病作用是通过提高肝脏、肌肉和脂肪组织对"}, {"probability": {"variance": 0.002263, "average": 0.984305, "min": 0.803164}, "location": {"width": 829, "top": 1493, "height": 47, "left": 194}, "words": "胰岛素的敏感性而实现,并且在脂肪组织中使胰岛素调控的葡萄糖转运因子GLUT-4的基因"}, {"probability": {"variance": 0.001765, "average": 0.97672, "min": 0.839871}, "location": {"width": 761, "top": 1524, "height": 43, "left": 197}, "words": "表达增加。本品单独使用不会使2型糖尿病和/或糖耐量诚低的模型动物出现低血糖"}], "language": 3}